Frontiers in Pharmacology·YesterdayTirzepatide versus other anti-diabetic agents for the prevention of diabetic foot complications in patients with type 2 diabetesStudy in peopleInterventionsPaper
Drug Design, Development and Therapy·4 OctPrior Use of GLP-1 Receptor Agonists versus SGLT2 Inhibitors and Clinical Outcomes After Sepsis in Patients with Type 2 Diabetes: A Propensity Score-Matched Cohort StudyCohort study of 11,969 peopleSepsisPaper
Nature Communications·22 SepGlucagon-like Peptide-1 Receptor Agonists and Risk of Tuberculosis in Type 2 DiabetesStudy in peoplePopulationsPaper
Diagnostics·15 SepExplainable Machine Learning Models for Predicting Functional and Pain Recovery After Fragility Fracture SurgeryStudy in peopleBiomarkersPaper
Diabetes, Obesity & Metabolism·15 SepPsychiatric Safety of GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Adolescents With ObesityCohort study of 9,222 peopleGLP-1 receptor agonistsPaper
Frontiers in Endocrinology·9 SepTirzepatide and the risk of asthma exacerbations in patients with type 2 diabetesCohort study of 30,292 peopleTirzepatidePaper
Frontiers in Urology·22 AugGlucagon-like peptide-1 receptor agonist versus other anti-diabetic agents on patients with prostate cancer undergoing androgen-deprivation therapyCohort study of 1,009 peopleGLP-1 receptor agonistsPaper
QJM·17 AugAssociations Between Glucagon-like Peptide-1 Receptor Agonists and Respiratory Outcomes in Chronic Obstructive pulmonary disease and DiabetesCohort study in peopleGLP-1 receptor agonistsPaper
Nephrology, Dialysis, Transplantation·7 AugSepsis and Infectious Outcomes for GLP-r Agonists in CKD plus Type 2 DiabetesCohort study of 21,035 peopleGLP-1 receptor agonistsPaper
Frontiers in Nutrition·7 AugSerum zinc deficiency and progression of cardiovascular- kidney-metabolic syndromeStudy in peoplePopulationsPaper